New drug aims to save kidneys: 3,000-Patient trial launches

NCT ID NCT06866236

Not yet recruiting Disease control Sponsor: Ebima Clifford Okundaye Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests a new drug called QRX3 in 3,000 people with chronic kidney disease whose kidney function is declining. The goal is to see if QRX3 can improve kidney function and slow the need for dialysis. Participants take QRX3 capsules, and researchers measure changes in kidney filtration rates and protein levels in urine over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QRX-3 (a drug that targets kidney function)
What this could lead to: If successful, this could provide a new treatment option to slow kidney decline and reduce the need for dialysis in people with chronic kidney disease.
What could go wrong: This is an early-phase trial (phase 2/3) with a large but specific group of participants, so results may not apply to all kidney disease patients. The drug may not improve kidney function or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury chronic kidney disease chronic renal failure syndrome kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY CHRONIC KIDNEY DISEASES KIDNEY FAILURE

Contacts and locations

Show contact details

Locations

Neukidney Inc

Pasedena, Texas, 77504, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.